Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

178 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Significant differential effects of alendronate, estrogen, or combination therapy on the rate of bone loss after discontinuation of treatment of postmenopausal osteoporosis. A randomized, double-blind, placebo-controlled trial.
Greenspan SL, Emkey RD, Bone HG, Weiss SR, Bell NH, Downs RW, McKeever C, Miller SS, Davidson M, Bolognese MA, Mulloy AL, Heyden N, Wu M, Kaur A, Lombardi A. Greenspan SL, et al. Among authors: bell nh. Ann Intern Med. 2002 Dec 3;137(11):875-83. doi: 10.7326/0003-4819-137-11-200212030-00008. Ann Intern Med. 2002. PMID: 12458987 Clinical Trial.
Alendronate and estrogen effects in postmenopausal women with low bone mineral density. Alendronate/Estrogen Study Group.
Bone HG, Greenspan SL, McKeever C, Bell N, Davidson M, Downs RW, Emkey R, Meunier PJ, Miller SS, Mulloy AL, Recker RR, Weiss SR, Heyden N, Musliner T, Suryawanshi S, Yates AJ, Lombardi A. Bone HG, et al. J Clin Endocrinol Metab. 2000 Feb;85(2):720-6. doi: 10.1210/jcem.85.2.6393. J Clin Endocrinol Metab. 2000. PMID: 10690882 Clinical Trial.
Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The Alendronate Phase III Osteoporosis Treatment Study Group.
Liberman UA, Weiss SR, Bröll J, Minne HW, Quan H, Bell NH, Rodriguez-Portales J, Downs RW Jr, Dequeker J, Favus M. Liberman UA, et al. Among authors: bell nh. N Engl J Med. 1995 Nov 30;333(22):1437-43. doi: 10.1056/NEJM199511303332201. N Engl J Med. 1995. PMID: 7477143 Free article. Clinical Trial.
Increments in bone mineral density of the lumbar spine and hip and suppression of bone turnover are maintained after discontinuation of alendronate in postmenopausal women.
Stock JL, Bell NH, Chesnut CH 3rd, Ensrud KE, Genant HK, Harris ST, McClung MR, Singer FR, Yood RA, Pryor-Tillotson S, Wei L, Santora AC 2nd. Stock JL, et al. Among authors: bell nh. Am J Med. 1997 Oct;103(4):291-7. doi: 10.1016/s0002-9343(97)00130-7. Am J Med. 1997. PMID: 9382121 Clinical Trial.
Advances in the treatment of osteoporosis.
Bell NH. Bell NH. Curr Drug Targets Immune Endocr Metabol Disord. 2001 May;1(1):93-102. doi: 10.2174/1568008013341622. Curr Drug Targets Immune Endocr Metabol Disord. 2001. PMID: 12476784 Review.
Comparison of nonrandomized trials with slow-release sodium fluoride with a randomized placebo-controlled trial in postmenopausal osteoporosis.
Pak CY, Adams-Huet B, Sakhaee K, Bell NH, Licata A, Johnston C, Rubin B, Bonnick S, Piziak V, Graham H, Ballard J, Berger R, Fears W, Breslau N, Rubin C. Pak CY, et al. Among authors: bell nh. J Bone Miner Res. 1996 Feb;11(2):160-8. doi: 10.1002/jbmr.5650110204. J Bone Miner Res. 1996. PMID: 8822339 Free article. Clinical Trial.
178 results